Journal
DRUGS
Volume 75, Issue 9, Pages 935-945Publisher
ADIS INT LTD
DOI: 10.1007/s40265-015-0410-1
Keywords
-
Categories
Funding
- Medical Research Council (MRC)
- Biotechnology and Biological Sciences Research Council (BBSRC)
- National Institute for Health Research (NIHR)
- Integrative Mammalian Biology (IMB) Capacity Building Award
- NIHR Imperial Biomedical Research Centre Funding Scheme
- MRC Clinical Research Training Fellowship
- [FP7-HEALTH-2009-241592 EuroCHIP]
- BBSRC [BB/L004259/1] Funding Source: UKRI
- MRC [G7811974, MR/L013088/1, MR/K023667/1, MR/K02115X/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/L004259/1] Funding Source: researchfish
- Medical Research Council [MR/K02115X/1, MR/K023667/1, G7811974, MR/L013088/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10080, NF-SI-0513-10029, NF-SI-0507-10337] Funding Source: researchfish
Ask authors/readers for more resources
There is an urgent need for effective pharmacological therapies to help tackle the growing obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of a number of novel anti-obesity drugs. The majority of these influence hypothalamic appetite pathways via dopaminergic or serotoninergic signalling. Some are combination therapies, allowing lower doses to minimize the potential for off-target effects. An alternative approach is to mimic endogenous satiety signals using long-lasting forms of peripheral appetite-suppressing hormones. There is also considerable interest in targeting thermogenesis by brown adipose tissue to increase resting energy expenditure. Obesity pharmacotherapy has seen several false dawns, but improved understanding of the pathways regulating energy balance, and better-designed trials, give many greater confidence that recently approved agents will be both efficacious and safe. Nevertheless, a number of issues from preclinical and clinical development continue to attract debate, and additional large-scale trials are still required to address areas of uncertainty.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available